SG10201705061RA - Treatment of Diseases of Endothelial Dysfunction and Inflammation - Google Patents

Treatment of Diseases of Endothelial Dysfunction and Inflammation

Info

Publication number: SG10201705061RA
Authority: SG; Singapore
Prior art keywords: inflammation; diseases; treatment; endothelial dysfunction; dysfunction
Prior art date: 2012-12-12

Application number

SG10201705061RA

Inventor

Itescu Silviu

Ghosh Peter

Gregory KIMPTON Wayne

Reeves Bailey Simon

Original Assignee

Mesoblast Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-12

Filing date

2013-12-12

Publication date

2017-07-28

2013-12-12 Application filed by Mesoblast Inc filed Critical Mesoblast Inc

2017-07-28 Publication of SG10201705061RA publication Critical patent/SG10201705061RA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Developmental Biology & Embryology (AREA)
Immunology (AREA)
Cardiology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Virology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)

SG10201705061RA 2012-12-12 2013-12-12 Treatment of Diseases of Endothelial Dysfunction and Inflammation SG10201705061RA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261736361P	2012-12-12	2012-12-12

Publications (1)

Publication Number	Publication Date
SG10201705061RA true SG10201705061RA (en)	2017-07-28

Family

ID=50933585

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201705061RA SG10201705061RA (en)	2012-12-12	2013-12-12	Treatment of Diseases of Endothelial Dysfunction and Inflammation
SG11201504340YA SG11201504340YA (en)	2012-12-12	2013-12-12	Treatment of diseases of endothelial dysfunction and inflammation

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201504340YA SG11201504340YA (en)	2012-12-12	2013-12-12	Treatment of diseases of endothelial dysfunction and inflammation

Country Status (11)

Country	Link
US (2)	US20160175360A1 (en)
EP (2)	EP2931876B1 (en)
JP (5)	JP6572130B2 (en)
KR (3)	KR102506612B1 (en)
CN (2)	CN105358163B (en)
AU (4)	AU2013360024B2 (en)
CA (1)	CA2893942C (en)
ES (1)	ES2742035T3 (en)
IL (1)	IL239308A0 (en)
SG (2)	SG10201705061RA (en)
WO (1)	WO2014089623A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110014701A1 (en)	2007-12-04	2011-01-20	Proteobioactives Pty Ltd.	Protection of Progenitor Cells and Regulation of Their Differentiation
JP6572130B2 (en) *	2012-12-12	2019-09-04	メソブラスト、インコーポレイテッド	Treatment of diseases of endothelial dysfunction and inflammation
JPWO2022114111A1 (en) *	2020-11-27	2022-06-02

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
WO1992001070A1 (en)	1990-07-09	1992-01-23	The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce	High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
CA2115742A1 (en)	1991-08-20	1993-03-04	Ronald G. Crystal	Adenovirus mediated transfer of genes to the gastrointestinal tract
PT1493439E (en)	1997-04-02	2012-01-10	Brigham & Womens Hospital	Means of ascertaining an individual` s risk profile for atherosclerotic disease
AUPQ147799A0 (en)	1999-07-07	1999-07-29	Medvet Science Pty. Ltd.	Mesenchymal precursor cell
AU2003901668A0 (en)	2003-03-28	2003-05-01	Medvet Science Pty. Ltd.	Non-haemopoietic precursor cells
DE19939781C2 (en)	1999-08-21	2003-06-18	Schott Glas	Skull crucible for melting or refining inorganic substances, especially glasses and glass ceramics
US20080095749A1 (en) *	2004-03-22	2008-04-24	Sudeepta Aggarwal	Mesenchymal stem cells and uses therefor
KR101441026B1 (en)	2004-09-24	2014-10-01	메소블라스트, 아이엔씨.	Amplified pluripotent mesenchymal progenitor cells and their uses
KR101446634B1 (en)	2005-04-12	2014-10-16	메소블라스트, 아이엔씨.	Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
JP2008544957A (en) *	2005-05-10	2008-12-11	ユナイテッドステイツオブアメリカデパートメントオブヴェテランズアフェアーズ	Treatment of renal diseases and multiple organ failure by mesenchymal stem cells and mesenchymal stem cell conditioned medium
US20080260703A1 (en) *	2007-04-23	2008-10-23	Medistem Labortories	Treatment of Insulin Resistance and Diabetes
US8124071B2 (en) *	2007-11-30	2012-02-28	New York Medical College	Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
EP2227238A2 (en) *	2007-11-30	2010-09-15	New York Medical College	Compositions comprising vascular and myocyte progenitor cells and methods of their use
US20110014701A1 (en) *	2007-12-04	2011-01-20	Proteobioactives Pty Ltd.	Protection of Progenitor Cells and Regulation of Their Differentiation
US20110200612A1 (en) *	2008-06-30	2011-08-18	Michael Schuster	Treatment of eye diseases and excessive neovascularization using combined therapy
EP2350266B1 (en) *	2008-11-20	2015-07-29	Mesoblast, Inc.	Method for treating or preventing a pancreatic dysfunction
WO2010138180A2 (en) *	2009-05-26	2010-12-02	The University Of Vermont And State Agriculture College	Compositions and methods for cardiac tissue repair
WO2011073521A1 (en) *	2009-12-15	2011-06-23	Petri Salven	Methods for enriching adult-derived endothelial progenitor cells and uses thereof
WO2012047733A2 (en) *	2010-09-29	2012-04-12	Aidan Research And Consulting, Llc.	Treatment of acne by conditioned media
US9405700B2 (en)	2010-11-04	2016-08-02	Sonics, Inc.	Methods and apparatus for virtualization in an integrated circuit
CN103841983B (en) *	2011-06-03	2018-11-02	麦瑟布莱斯特公司	Methods of treating or preventing neurological diseases
KR101786862B1 (en) *	2011-07-04	2017-10-18	메소블라스트, 아이엔씨.	Methods of treating or preventing rheumatic disease
AU2013296611B2 (en) *	2012-08-01	2017-11-23	United Therapeutics Corporation	Treatment of pulmonary arterial hypertension with mesenchymal stem cells
JP6572130B2 (en) *	2012-12-12	2019-09-04	メソブラスト、インコーポレイテッド	Treatment of diseases of endothelial dysfunction and inflammation
ES2697573T3 (en) *	2013-01-09	2019-01-25	United Therapeutics Corp	Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

2013
- 2013-12-12 JP JP2015546770A patent/JP6572130B2/en active Active
- 2013-12-12 SG SG10201705061RA patent/SG10201705061RA/en unknown
- 2013-12-12 CA CA2893942A patent/CA2893942C/en active Active
- 2013-12-12 AU AU2013360024A patent/AU2013360024B2/en active Active
- 2013-12-12 CN CN201380072732.5A patent/CN105358163B/en active Active
- 2013-12-12 KR KR1020227005920A patent/KR102506612B1/en active Active
- 2013-12-12 WO PCT/AU2013/001452 patent/WO2014089623A1/en not_active Ceased
- 2013-12-12 ES ES13862555T patent/ES2742035T3/en active Active
- 2013-12-12 EP EP13862555.3A patent/EP2931876B1/en active Active
- 2013-12-12 KR KR1020217004422A patent/KR102367981B1/en active Active
- 2013-12-12 EP EP19174698.1A patent/EP3556850A1/en active Pending
- 2013-12-12 CN CN202010796960.9A patent/CN111840329B/en active Active
- 2013-12-12 SG SG11201504340YA patent/SG11201504340YA/en unknown
- 2013-12-12 US US14/650,172 patent/US20160175360A1/en not_active Abandoned
- 2013-12-12 KR KR1020157017531A patent/KR102217962B1/en active Active
2015
- 2015-06-09 IL IL239308A patent/IL239308A0/en unknown
2019
- 2019-04-29 AU AU2019202960A patent/AU2019202960B2/en active Active
- 2019-07-01 JP JP2019123243A patent/JP6829288B2/en active Active
2021
- 2021-01-21 JP JP2021008250A patent/JP7201715B2/en active Active
- 2021-10-12 AU AU2021250848A patent/AU2021250848A1/en not_active Abandoned
2022
- 2022-12-22 JP JP2022206042A patent/JP2023030116A/en active Pending
2023
- 2023-10-04 US US18/481,041 patent/US20240115618A1/en active Pending
2024
- 2024-07-11 JP JP2024111736A patent/JP2024147655A/en active Pending
- 2024-10-10 AU AU2024227208A patent/AU2024227208A1/en active Pending

Also Published As

Publication number	Publication date
KR102506612B1 (en)	2023-03-06
AU2013360024B2 (en)	2019-02-28
HK1210209A1 (en)	2016-04-15
KR102367981B1 (en)	2022-02-25
CN105358163A (en)	2016-02-24
AU2019202960B2 (en)	2021-07-29
JP2023030116A (en)	2023-03-07
EP2931876A1 (en)	2015-10-21
EP2931876B1 (en)	2019-05-29
JP2019214571A (en)	2019-12-19
CN111840329A (en)	2020-10-30
JP6572130B2 (en)	2019-09-04
US20160175360A1 (en)	2016-06-23
CA2893942A1 (en)	2014-06-19
WO2014089623A1 (en)	2014-06-19
AU2024227208A1 (en)	2024-10-31
EP2931876A4 (en)	2016-05-25
JP7201715B2 (en)	2023-01-10
US20240115618A1 (en)	2024-04-11
JP2021073240A (en)	2021-05-13
AU2019202960A1 (en)	2019-05-16
JP2024147655A (en)	2024-10-16
EP3556850A1 (en)	2019-10-23
JP2016504311A (en)	2016-02-12
JP6829288B2 (en)	2021-02-10
KR102217962B1 (en)	2021-02-22
SG11201504340YA (en)	2015-07-30
AU2013360024A1 (en)	2015-07-02
AU2021250848A1 (en)	2021-11-04
CN105358163B (en)	2020-09-11
CN111840329B (en)	2024-10-15
CA2893942C (en)	2023-03-28
KR20220029758A (en)	2022-03-08
KR20210021104A (en)	2021-02-24
IL239308A0 (en)	2015-07-30
ES2742035T3 (en)	2020-02-12
KR20150093732A (en)	2015-08-18

Publication	Publication Date	Title
ZA202100373B (en)	2023-04-26	Therapeutically active compounds and their methods of use
IL261768B (en)	2021-05-31	Devices and methods for the treatment of tissue
IL239368A0 (en)	2015-07-30	Ppar-sparing thiazolidiones and combinations for the treatment of neurodegenerative diseases
IL237070A0 (en)	2015-03-31	Treatment of immune-related and inflammatory diseases
ZA201402615B (en)	2015-04-29	Prevention and treatment of ocular conditions
ZA201405163B (en)	2018-05-30	Therapeutically active compounds and their methods of use
EP2804850A4 (en)	2015-09-23	Therapeutically active compounds and their methods of use
IL233111A0 (en)	2014-08-03	Treatment of inflammation
PL2830654T3 (en)	2020-02-28	METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION
PL2668183T3 (en)	2018-10-31	Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
PL2668182T3 (en)	2018-11-30	Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
EP2574172A4 (en)	2013-10-30	Materials and methods for treatment of inflammation
EP2869833A4 (en)	2015-11-18	Treatment of inflammatory skin disorders
ZA201503979B (en)	2017-11-29	Treatment of diseases involving mucin
PL2892556T3 (en)	2019-11-29	Compositions and methods relating to the treatment of diseases
EP2726079A4 (en)	2014-12-17	Method of administration and treatment
ZA201401800B (en)	2015-07-29	Novel plant defensins and use in the treatment of proliferative diseases
IL239308A0 (en)	2015-07-30	Treatment of diseases of endothelial dysfunction and inflammation
IL233080A0 (en)	2014-07-31	Bisarylsulfonamides useful in the treatment of inflammation and cancer
PL2744497T3 (en)	2016-10-31	Therapeutic combinations of netupitant and palonosetron
GB201100651D0 (en)	2011-03-02	Treatment of inflammation
AU2012900272A0 (en)	2012-02-16	Treatment and inhibition of corneal erosions
GB201201779D0 (en)	2012-03-14	Treatment of inflammatory disorders
AU2012901301A0 (en)	2012-04-19	Treatment of inflammatory and immune disorders